DASALIEVA 50 mg contains Dasatinib, an oral tyrosine kinase inhibitor (TKI). It inhibits BCR-ABL kinase and SRC family kinases, blocking abnormal signaling pathways responsible for uncontrolled proliferation of leukemic cells. Dasatinib is effective in many cases resistant or intolerant to imatinib.

Dasatinib is indicated for:

1. Chronic Myeloid Leukemia (CML)
    – Chronic, accelerated, or blast phase
    – Patients resistant or intolerant to prior therapy (including imatinib)

2. Philadelphia chromosome–positive Acute Lymphoblastic Leukemia (Ph+ ALL)
    – Adult and pediatric patients (as per treatment protocol)

Common side effects:

•  Myelosuppression (anemia, neutropenia, thrombocytopenia)

•  Fatigue

•  Diarrhea

•  Headache

•  Skin rash

Serious side effects:

•  Pleural effusion

•  Pulmonary arterial hypertension (rare)

•  QT interval prolongation

•  Bleeding disorders

Regular CBC monitoring, assessment for respiratory symptoms, and cardiac evaluation are important.

Dosage depends on disease phase and patient tolerance.

Typical adult dosing:

•  Chronic phase CML: 100 mg once daily

•  Advanced phase CML / Ph+ ALL: 140 mg once daily

50 mg tablets are commonly used for dose titration or reduction.


NOTE: This medicine should be taken only under a doctor’s supervision.